Année d’arrivée au Centre



  • Docteur  en Médecine Université Catholique de Louvain (B) Spécialité Médecine Interne/Hélmatologie

Interventions pratiquées ou expertise

  • Syndrome  Myélodysplasique (GFM)
  • Lymphome Hodgkinien (LYSA)

Sociétés savantes

  • GFM
  • SFH
  • SFGM
  • LYSA

Publications majeures

  • Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
    Haematologica. 2010 Jun;95(6):892-9.
  • Development of a multiplex PCR assay for the detection of genomic copy number changes in myelodysplastic syndromes.
    Leuk Res. 2012 May;36(5):e93-7
  • Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients.
    Leuk Lymphoma. 2013 Nov;54(11):2399-404.
  • Hypoalbuminemia and hypergammaglobulinemia are associated with an increased infection risk in patients with myeloid malignancies treated with azacitidine. A 3-year monocentric retrospective study.
    Leuk Lymphoma. 2016;57(6):1491-3
  • Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.
    Haematologica. 2016 Sep;101(9):1094-101.
  • Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
    Bone Marrow Transplant. 2016 Jul;51(7):928-32.
  • Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Lancet Haematol. 2018 Feb;5(2):e63-e72.
  • Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom.
    Br J Haematol. 2019 Jan;184(2):202-214.
  • PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
    Lancet Oncol. 2019 Feb;20(2):202-215.
  • Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma.
    Radiology. 2020 Apr 14:192056.